首页 产品中心
  • Plerixafor 8HCl (AMD3100 8HCl)

    • 普乐沙福八盐酸盐
    货号: abs812798
    CAS号: 155148-31-5
    分子式: C28H54N8·8HCl
    分子量: 794.47
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs812798-5mg 现货 ¥529.00
    - +
    abs812798-10mg 现货 ¥686.00
    - +
    abs812798-25mg 现货 ¥1234.00
    - +
    大包装询价
    产品描述
    描述

    Plerixafor octahydrochloride(AMD3100 8HCl) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.

    纯度
    98%
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    别名
    普乐沙福八盐酸盐
    外观
    白色至类白色粉末
    可溶性/溶解性
    Water:100 mg/mL (125.87 mM)
    生物活性
    靶点
    CXCR
    In vitro(体外研究)
    The CXCR4 inhibitor Plerixafor (AMD3100) is a potent inhibitor of CXCL12-mediated chemotaxis (IC50, 5.7 nM) with a potency slightly better than its affinity for CXCR4. Treating the cells with CCX771 or CXCL11 has no effect on CXCL12-mediated MOLT-4 or U937 TEM. In contrast, 10 μM Plerixafor inhibits CXCL12-mediated TEM in both cells lines. Plerixafor (10 μM)-treated cells show a moderate reduction in cell proliferation compared to CXCL12-stimulated cells, which do not reach statistical significance.
    In vivo(体内研究)
    Plerixafor (2 mg/kg) administration to UUO mice exacerbates renal interstitial T cell infiltration, resulting in increased production of the pro-inflammatory cytokines IL-6 and IFN-γ and decreased expression of the anti-inflammatory cytokine IL-10. Both perivascular and interstitial fibrosis are significantly reduced by the CXCR4 antagonist, Plerixafor (AMD3100) at 8 weeks. LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0 张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要咨询”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要咨询

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0